{"id":495142,"date":"2020-07-10T13:42:01","date_gmt":"2020-07-10T13:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=495142"},"modified":"2020-07-10T13:42:01","modified_gmt":"2020-07-10T13:42:01","slug":"myasthenia-gravis-market-insights-market-share-epidemiology-and-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myasthenia-gravis-market-insights-market-share-epidemiology-and-forecast-2030_495142.html","title":{"rendered":"Myasthenia Gravis Market Insights, Market Share, Epidemiology and Forecast 2030"},"content":{"rendered":"
\"Myasthenia<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

(Albany, US) DelveInsight<\/strong> launched its new report on Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/span><\/strong><\/p>\n

DelveInsight’s “Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>” report delivers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

View report<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-market<\/a><\/p>\n

The key facts of the report:<\/strong><\/p>\n

1. Among the European countries, Spain had the highest Myasthenia Gravis prevalence with around 15,275 cases, followed by Germany with about 12,400 cases in 2016.
2. Japan had the lowest prevalent population of Myasthenia Gravis in 2016, with 14,985 cases.<\/p>\n

Key benefits of the report:<\/strong>
1. Myasthenia Gravis market report covers a descriptive overview and comprehensive insight of the Myasthenia Gravis epidemiology and Myasthenia Gravis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Myasthenia Gravis market report provides insights on the current and emerging therapies.
3. Myasthenia Gravis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Myasthenia Gravis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myasthenia Gravis market. <\/p>\n

Request for a free sample report<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-market<\/a><\/p>\n

The key players in Myasthenia Gravis market are:<\/strong><\/p>\n

1. UCB Pharma
2. Novartis
3. Argenx
4. Ra Pharmaceuticals
and many others.<\/p>\n

The launch of the emerging therapies is expected to significantly impact Myasthenia Gravis treatment scenario in the upcoming years:-<\/strong>
Drugs covered<\/strong>
1. Rozanolixizumab
2. CFZ533
3. Efgartigimod
4. RA101495
And many others<\/p>\n

Table of contents:<\/strong>
1. Key Insights
2. Myasthenia Gravis Market Overview at a Glance
3. Myasthenia Gravis Disease Overview
4. Myasthenia Gravis Epidemiology and Patient Population
5. Country Wise Myasthenia Gravis Epidemiology
5.1. United States
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. United Kingdom
5.7. Japan
6. Myasthenia Gravis Current Treatment Practices
7. Unmet Needs
8. Myasthenia Gravis Marketed drugs
8.1. Key cross competition- Marketed drugs
8.2. Mestinon: Valeant Pharmaceuticals
8.3. Soliris: Alexion Pharmaceuticals
8.4. Prograf: Astellas Pharma
8.5. Venoglobulin IH: Mitsubishi Tanabe Pharma
9. Myasthenia Gravis Emerging Therapies
9.1. Key cross competition- Emerging Therapies
9.2. Rozanolixizumab: UCB Pharma
9.3. CFZ533: Novartis
9.4. Efgartigimod : Argenx
9.5. RA101495: Ra Pharmaceuticals
9.6. Firdapse: Catalyst Pharmaceuticals
9.7. Hizentra: CSL Behring
9.8. IGIV-C: Grifols Therapeutics
10. Myasthenia Gravis 7 Major Market Analysis
11. Market Outlook by Country
11.1. The United States: Market Outlook
11.2. United States Market Size
11.3. EU-5 Countries: Market Outlook
11.4. Germany
11.5. France
11.6. Italy
11.7. Spain
11.8. United Kingdom
11.9. Japan: Market Outlook
12. Market Drivers
13. Market Barriers
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight<\/p>\n

Related reports:<\/strong><\/p>\n

Myasthenia Gravis – Epidemiology Forecast to 2030<\/a><\/strong><\/p>\n

Myasthenia Gravis – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020<\/a><\/strong><\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-495142","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/495142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=495142"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/495142\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=495142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=495142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=495142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}